Fluorescence lifetime imaging ophthalmoscopy: autofluorescence imaging and beyond.
Journal
Eye (London, England)
ISSN: 1476-5454
Titre abrégé: Eye (Lond)
Pays: England
ID NLM: 8703986
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
14
10
2020
accepted:
04
11
2020
revised:
20
10
2020
pubmed:
4
12
2020
medline:
22
6
2021
entrez:
3
12
2020
Statut:
ppublish
Résumé
Fluorescence lifetime imaging ophthalmoscopy, FLIO, has gained large interest in the scientific community in the recent years. It is a noninvasive imaging modality that has been shown to provide additional information to conventional imaging modalities. The FLIO device is based on a Heidelberg Engineering Spectralis system. Autofluorescence lifetimes are excited at 473 nm and recorded in two spectral wavelength channels, a short spectral channel (SSC, 498-560 nm) and a long spectral channel (LSC, 560-720 nm). Typically, mean autofluorescence lifetimes in a 30° retinal field are investigated. FLIO shows a clear benefit for imaging different retinal diseases. For example, in age-related macular degeneration (AMD), ring patterns of prolonged FLIO lifetimes 1.5-3.0 mm from the fovea can be appreciated. Macular telangiectasia type 2 (MacTel) shows a different pattern, with prolonged FLIO lifetimes within the typical MacTel zone. In Stargardt disease, retinal flecks can be appreciated even before they are visible with other imaging modalities. Early hydroxychloroquine toxicity appears to be detectable with FLIO. This technique has more potential that has yet to be discovered. This review article focuses on current knowledge as well as pitfalls of this technology. It highlights clinical benefits of FLIO imaging in different ophthalmic and systemic diseases, and provides an outlook with perspectives from the authors. 摘要: 近年来, 荧光活体实时成像检眼镜(FLIO)在科学界引起了广泛的兴趣。它是一种非侵入性的成像方式, 已被证明可以为其他常规成像方式提供更多额外的信息。FLIO装置基于海德堡的spectralis系统。FLIO的激发波长为473 nm, 并记录在两个光谱波长的通道中, 一个是短光谱通道(SSC, 498–560 nm), 另一个是长光谱通道(LSC, 560–720 nm)。一般用于研究30度视网膜范围的自体荧光。FLIO在不同视网膜疾病中成像优势明显。例如, 在与年龄相关的黄斑变性(AMD)中, 可以观察到距中央凹1.5 mm至3.0 mm的FLIO活体的环形图案;在2型黄斑毛细血管扩张(MacTel)中可观察到不同类型影像, 但FLIO影像在MacTel区域的不同表现;在Stargardt病中, 视网膜斑点可以在其他成像方式检测之前就可被识别出来;早期的羟氯喹视网膜病变也可以用FLIO进行识别。因此这项技术还有更多有待开发的潜力。这篇综述重点介绍了该技术的现状和缺陷。强调了FLIO成像在不同眼科和全身性疾病中的临床优势, 并且提出了对于该技术的展望。.
Autres résumés
Type: Publisher
(chi)
摘要: 近年来, 荧光活体实时成像检眼镜(FLIO)在科学界引起了广泛的兴趣。它是一种非侵入性的成像方式, 已被证明可以为其他常规成像方式提供更多额外的信息。FLIO装置基于海德堡的spectralis系统。FLIO的激发波长为473 nm, 并记录在两个光谱波长的通道中, 一个是短光谱通道(SSC, 498–560 nm), 另一个是长光谱通道(LSC, 560–720 nm)。一般用于研究30度视网膜范围的自体荧光。FLIO在不同视网膜疾病中成像优势明显。例如, 在与年龄相关的黄斑变性(AMD)中, 可以观察到距中央凹1.5 mm至3.0 mm的FLIO活体的环形图案;在2型黄斑毛细血管扩张(MacTel)中可观察到不同类型影像, 但FLIO影像在MacTel区域的不同表现;在Stargardt病中, 视网膜斑点可以在其他成像方式检测之前就可被识别出来;早期的羟氯喹视网膜病变也可以用FLIO进行识别。因此这项技术还有更多有待开发的潜力。这篇综述重点介绍了该技术的现状和缺陷。强调了FLIO成像在不同眼科和全身性疾病中的临床优势, 并且提出了对于该技术的展望。.
Identifiants
pubmed: 33268846
doi: 10.1038/s41433-020-01287-y
pii: 10.1038/s41433-020-01287-y
pmc: PMC7852552
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
93-109Références
Lakowicz JR. Principles of fluorescence spectroscopy. New York: Springer; 2007.
Marcu L. Fluorescence lifetime techniques in medical applications. Ann Biomed Eng. 2012;40:304–31.
pubmed: 22273730
pmcid: 3368954
doi: 10.1007/s10439-011-0495-y
Lakowicz JR, Szmacinski H, Nowaczyk K, Johnson ML. Fluorescence lifetime imaging of free and protein-bound NADH. Proc Natl Acad Sci USA. 1992;89:1271–5.
pubmed: 1741380
doi: 10.1073/pnas.89.4.1271
Schweitzer D, Kolb A, Hammer M, Anders R. Time-correlated measurement of autofluorescence. A method to detect metabolic changes in the fundus. Ophthalmologe. 2002;99:774–9.
pubmed: 12376853
doi: 10.1007/s00347-002-0656-3
Schweitzer D, Schenke S, Hammer M, Schweitzer F, Jentsch S, Birckner E, et al. Towards metabolic mapping of the human retina. Microsc Res Tech. 2007;70:410–9.
pubmed: 17393496
doi: 10.1002/jemt.20427
Becker W. The bh TCSPC handbook. 6th ed. Berlin: Becker & Hickl GmbH; 2014.
Sauer L, Schweitzer D, Ramm L, Augsten R, Hammer M, Peters S. Impact of macular pigment on fundus autofluorescence lifetimes. Investig Ophthalmol Vis Sci. 2015;56:4668–79.
doi: 10.1167/iovs.14-15335
ANSI. American National Standard for the Safe Use of Lasers. Orlando, FL: Laser Institute of America; 2000.
Delori FC, Webb RH, Sliney DH, American National Standards I. Maximum permissible exposures for ocular safety (ANSI 2000), with emphasis on ophthalmic devices. J Opt Soc Am A Opt Image Sci Vis. 2007;24:1250–65.
pubmed: 17429471
doi: 10.1364/JOSAA.24.001250
Sauer L, Andersen KM, Li B, Gensure RH, Hammer M, Bernstein PS. Fluorescence lifetime imaging ophthalmoscopy (FLIO) of macular pigment. Investig Ophthalmol Vis Sci. 2018;59:3094–103.
doi: 10.1167/iovs.18-23886
Sauer L, Vitale AS, Milliken CM, Modersitzki NK, Blount D, Bernstein PS. Autofluorescence lifetimes measured with fluorescence lifetime imaging ophthalmoscopy (FLIO) are affected by age, but not by pigmentation or gender. Transl Vis Sci Technol. 2020;9:2.
pubmed: 32879759
pmcid: 7442880
doi: 10.1167/tvst.9.9.2
Klemm M, Dietzel A, Haueisen J, Nagel E, Hammer M, Schweitzer D. Repeatability of autofluorescence lifetime imaging at the human fundus in healthy volunteers. Curr Eye Res. 2013;38:793–801.
pubmed: 23530995
doi: 10.3109/02713683.2013.779723
Dysli C, Quellec G, Abegg M, Menke MN, Wolf-Schnurrbusch U, Kowal J, et al. Quantitative analysis of fluorescence lifetime measurements of the macula using the fluorescence lifetime imaging ophthalmoscope in healthy subjects. Investig Ophthalmol Vis Sci. 2014;55:2106–13.
doi: 10.1167/iovs.13-13627
Kwon S, Borrelli E, Fan W, Ebraheem A, Marion KM, Sadda SR. Repeatability of fluorescence lifetime imaging ophthalmoscopy in normal subjects with mydriasis. Transl Vis Sci Technol. 2019;8:15.
pubmed: 31114715
pmcid: 6506203
doi: 10.1167/tvst.8.3.15
Klemm M, Sauer L, Klee S, Link D, Peters S, Hammer M, et al. Bleaching effects and fluorescence lifetime imaging ophthalmoscopy. Biomed Opt Express. 2019;10:1446–61.
pubmed: 30891358
pmcid: 6420301
doi: 10.1364/BOE.10.001446
Hammer M, Konigsdorffer E, Liebermann C, Framme C, Schuch G, Schweitzer D, et al. Ocular fundus auto-fluorescence observations at different wavelengths in patients with age-related macular degeneration and diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2008;246:105–14.
pubmed: 17653752
doi: 10.1007/s00417-007-0639-9
Sauer L, Peters S, Schmidt J, Schweitzer D, Klemm M, Ramm L, et al. Monitoring macular pigment changes in macular holes using fluorescence lifetime imaging ophthalmoscopy. Acta Ophthalmol. 2017;95:481–92.
pubmed: 27775222
doi: 10.1111/aos.13269
Ermakov IV, McClane RW, Gellermann W, Bernstein PS. Resonant Raman detection of macular pigment levels in the living human retina. Opt Lett. 2001;26:202–4.
pubmed: 18033547
doi: 10.1364/OL.26.000202
Jaggi DSY, Dysli C, Wolf S, Zinkernagel M. Fluorescence lifetime imaging ophthalmoscopy and the influence of oral lutein supplementation on macular pigment: a preliminary study report. Paris: EURetina; 2019.
Greenberg JP, Duncker T, Woods RL, Smith RT, Sparrow JR, Delori FC. Quantitative fundus autofluorescence in healthy eyes. Investig Ophthalmol Vis Sci. 2013;54:5684–93.
doi: 10.1167/iovs.13-12445
Friedman DS, O’Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122:564–72.
pubmed: 15078675
doi: 10.1001/archopht.122.7.1019
Gehrs KM, Anderson DH, Johnson LV, Hageman GS. Age-related macular degeneration-emerging pathogenetic and therapeutic concepts. Ann Med. 2006;38:450–71.
pubmed: 17101537
pmcid: 4853957
doi: 10.1080/07853890600946724
Klein R, Cruickshanks KJ, Nash SD, Krantz EM, Nieto FJ, Huang GH, et al. The prevalence of age-related macular degeneration and associated risk factors. Arch Ophthalmol. 2010;128:750–8.
pubmed: 20547953
pmcid: 2896217
doi: 10.1001/archophthalmol.2010.92
Ferris FL 3rd, Wilkinson CP, Bird A, Chakravarthy U, Chew E, Csaky K, et al. Clinical classification of age-related macular degeneration. Ophthalmology. 2013;120:844–51.
pubmed: 23332590
doi: 10.1016/j.ophtha.2012.10.036
Age-Related Eye Disease Study 2 Research Group, Chew EY, Clemons TE, Sangiovanni JP, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmol. 2014;132:142–9.
doi: 10.1001/jamaophthalmol.2013.7376
Sauer L, Gensure RH, Andersen KM, Kreilkamp L, Hageman GS, Hammer M, et al. Patterns of fundus autofluorescence lifetimes in eyes of individuals with nonexudative age-related macular degeneration. Investig Ophthalmol Vis Sci. 2018;59:AMD65–77.
doi: 10.1167/iovs.17-23764
Dysli C, Fink R, Wolf S, Zinkernagel MS. Fluorescence lifetimes of drusen in age-related macular degeneration. Investig Ophthalmol Vis Sci. 2017;58:4856–62.
doi: 10.1167/iovs.17-22184
Dysli C, Wolf S, Zinkernagel MS. Autofluorescence lifetimes in geographic atrophy in patients with age-related macular degeneration. Investig Ophthalmol Vis Sci. 2016;57:2479–87.
doi: 10.1167/iovs.15-18381
Sauer L, Klemm M, Peters S, Schweitzer D, Schmidt J, Kreilkamp L, et al. Monitoring foveal sparing in geographic atrophy with fluorescence lifetime imaging ophthalmoscopy—a novel approach. Acta Ophthalmol. 2018;96:257–66.
pubmed: 29105362
doi: 10.1111/aos.13587
Hageman GS, Mullins RF. Molecular composition of drusen as related to substructural phenotype. Mol Vis. 1999;5:28.
pubmed: 10562652
Pepple K, Mruthyunjaya P. Retinal pigment epithelial detachments in age-related macular degeneration: classification and therapeutic options. Semin Ophthalmol. 2011;26:198–208.
pubmed: 21609233
doi: 10.3109/08820538.2011.570850
Sauer L, Komanski CB, Vitale AS, Hansen ED, Bernstein PS. Fluorescence lifetime imaging ophthalmoscopy (FLIO) in eyes with pigment epithelial detachments due to age-related macular degeneration. Investig Ophthalmol Vis Sci. 2019;60:3054–63.
doi: 10.1167/iovs.19-26835
Schweitzer D, Gaillard ER, Dillon J, Mullins RF, Russell S, Hoffmann B, et al. Time-resolved autofluorescence imaging of human donor retina tissue from donors with significant extramacular drusen. Investig Ophthalmol Vis Sci. 2012;53:3376–86.
doi: 10.1167/iovs.11-8970
Schweitzer D, Quick S, Schenke S, Klemm M, Gehlert S, Hammer M, et al. Comparison of parameters of time-resolved autofluorescence between healthy subjects and patients suffering from early AMD. Ophthalmologe. 2009;106:714–22.
pubmed: 19588156
doi: 10.1007/s00347-009-1975-4
Eisma JH, Dulle JE, Fort PE. Current knowledge on diabetic retinopathy from human donor tissues. World J Diabetes. 2015;6:312–20.
pubmed: 25789112
pmcid: 4360424
doi: 10.4239/wjd.v6.i2.312
Simo R, Hernandez C. Novel approaches for treating diabetic retinopathy based on recent pathogenic evidence. Prog Retin Eye Res. 2015;48:160–80.
pubmed: 25936649
doi: 10.1016/j.preteyeres.2015.04.003
Zhang X, Zeng H, Bao S, Wang N, Gillies MC. Diabetic macular edema: new concepts in patho-physiology and treatment. Cell Biosci. 2014;4:27.
pubmed: 24955234
pmcid: 4046142
doi: 10.1186/2045-3701-4-27
Guerin-Dubourg A, Cournot M, Planesse C, Debussche X, Meilhac O, Rondeau P, et al. Association between fluorescent advanced glycation end-products and vascular complications in type 2 diabetic patients. Biomed Res Int. 2017;2017:7989180.
pubmed: 29362717
pmcid: 5736945
doi: 10.1155/2017/7989180
Schmidt J, Peters S, Sauer L, Schweitzer D, Klemm M, Augsten R, et al. Fundus autofluorescence lifetimes are increased in non-proliferative diabetic retinopathy. Acta Ophthalmol. 2017;95:33–40.
pubmed: 27519815
doi: 10.1111/aos.13174
Schweitzer D, Deutsch L, Klemm M, Jentsch S, Hammer M, Peters S, et al. Fluorescence lifetime imaging ophthalmoscopy in type 2 diabetic patients who have no signs of diabetic retinopathy. J Biomed Opt. 2015;20:61106.
pubmed: 25769278
doi: 10.1117/1.JBO.20.6.061106
Schweitzer D. Metabolic mapping. In: Holz F, Spaide R, editors. Medical retina. Essentials in ophthalmology. Berlin: Springer Berlin Heidelberg; 2010. p. 107–23.
Schweitzer D, Quick S, Klemm M, Hammer M, Jentsch S, Dawczynski J. Time-resolved autofluorescence in retinal vascular occlusions. Ophthalmologe. 2010;107:1145–52.
pubmed: 20552361
doi: 10.1007/s00347-010-2195-7
Hammer M, Sauer L, Klemm M, Peters S, Schultz R, Haueisen J. Fundus autofluorescence beyond lipofuscin: lesson learned from ex vivo fluorescence lifetime imaging in porcine eyes. Biomed Opt Express. 2018;9:3078–91.
pubmed: 29984084
pmcid: 6033583
doi: 10.1364/BOE.9.003078
Abulrob A, Brunette E, Slinn J, Baumann E, Stanimirovic D. Dynamic analysis of the blood-brain barrier disruption in experimental stroke using time domain in vivo fluorescence imaging. Mol Imaging. 2008;7:7290.2008.00025.
doi: 10.2310/7290.2008.00025
Hamasaki DI, Kroll AJ. Experimental central retinal artery occlusion: an electrophysiological study. Arch Ophthalmol. 1968;80:243–8.
pubmed: 4969419
doi: 10.1001/archopht.1968.00980050245019
Semeraro F, Morescalchi F, Russo A, Gambicorti E, Pilotto A, Parmeggiani F, et al. Central serous chorioretinopathy: pathogenesis and management. Clin Ophthalmol. 2019;13:2341–52.
pubmed: 31819359
pmcid: 6897067
doi: 10.2147/OPTH.S220845
Iyer PG, Schwartz SG, Russell JF, Flynn HW. Central serous chorioretinopathy: multimodal imaging and management options. Case Rep Ophthalmol. 2020;2020:8890404.
Dysli C, Berger L, Wolf S, Zinkernagel MS. Fundus autofluorescence lifetimes and central serous chorioretinopathy. Retina. 2017;37:2151–61.
pubmed: 28099314
pmcid: 5690302
doi: 10.1097/IAE.0000000000001452
Charbel Issa P, Gillies MC, Chew EY, Bird AC, Heeren TF, Peto T, et al. Macular telangiectasia type 2. Prog Retin Eye Res. 2013;34:49–77.
pubmed: 23219692
doi: 10.1016/j.preteyeres.2012.11.002
Chew EY, Clemons TE, Peto T, Sallo FB, Ingerman A, Tao W, et al. Ciliary neurotrophic factor for macular telangiectasia type 2: results from a phase 1 safety trial. Am J Ophthalmol. 2015;159:659–66 e1.
pubmed: 25528956
doi: 10.1016/j.ajo.2014.12.013
Gantner ML, Eade K, Wallace M, Handzlik MK, Fallon R, Trombley J, et al. Serine and lipid metabolism in macular disease and peripheral neuropathy. N Engl J Med. 2019;381:1422–33.
pubmed: 31509666
pmcid: 7685488
doi: 10.1056/NEJMoa1815111
Sauer L, Gensure RH, Hammer M, Bernstein PS. Fluorescence lifetime imaging ophthalmoscopy: a novel way to assess macular telangiectasia type 2. Ophthalmol Retina 2018;2:587–98.
pubmed: 30116796
doi: 10.1016/j.oret.2017.10.008
Sauer L, Vitale AS, Andersen KM, Hart B, Bernstein PS. Fluorescence lifetime imaging ophthalmoscopy (FLIO) patterns in clinically unaffected children of macular telangiectasia type 2 (MacTel) patients. Retina. 2020;40:695–704.
pubmed: 31517727
doi: 10.1097/IAE.0000000000002646
Solberg Y, Dysli C, Wolf S, Zinkernagel MS. Fluorescence lifetime patterns in macular telangiectasia type 2. Retina. 2020;40:99–108.
pubmed: 30664123
doi: 10.1097/IAE.0000000000002411
Michaelides M, Hunt DM, Moore AT. The genetics of inherited macular dystrophies. J Med Genet. 2003;40:641–50.
pubmed: 12960208
pmcid: 1735576
doi: 10.1136/jmg.40.9.641
Stone EM, Andorf JL, Whitmore SS, DeLuca AP, Giacalone JC, Streb LM, et al. Clinically focused molecular investigation of 1000 consecutive families with inherited retinal disease. Ophthalmology. 2017;124:1314–31.
pubmed: 28559085
pmcid: 5565704
doi: 10.1016/j.ophtha.2017.04.008
Allikmets R, Singh N, Sun H, Shroyer NF, Hutchinson A, Chidambaram A, et al. A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. Nat Genet. 1997;15:236–46.
pubmed: 9054934
doi: 10.1038/ng0397-236
Boyer NP, Higbee D, Currin MB, Blakeley LR, Chen C, Ablonczy Z, et al. Lipofuscin and N-retinylidene-N-retinylethanolamine (A2E) accumulate in retinal pigment epithelium in absence of light exposure: their origin is 11-cis-retinal. J Biol Chem. 2012;287:22276–86.
pubmed: 22570475
pmcid: 3381188
doi: 10.1074/jbc.M111.329235
Zhang N, Tsybovsky Y, Kolesnikov AV, Rozanowska M, Swider M, Schwartz SB, et al. Protein misfolding and the pathogenesis of ABCA4-associated retinal degenerations. Hum Mol Genet. 2015;24:3220–37.
pubmed: 25712131
pmcid: 4424957
doi: 10.1093/hmg/ddv073
Cideciyan AV, Aleman TS, Swider M, Schwartz SB, Steinberg JD, Brucker AJ, et al. Mutations in ABCA4 result in accumulation of lipofuscin before slowing of the retinoid cycle: a reappraisal of the human disease sequence. Hum Mol Genet. 2004;13:525–34.
pubmed: 14709597
doi: 10.1093/hmg/ddh048
Dysli C, Wolf S, Hatz K, Zinkernagel MS. Fluorescence lifetime imaging in Stargardt disease: potential marker for disease progression. Investig Ophthalmol Vis Sci. 2016;57:832–41.
doi: 10.1167/iovs.15-18033
Solberg Y, Dysli C, Escher P, Berger L, Wolf S, Zinkernagel MS. Retinal flecks in Stargardt disease reveal characteristic fluorescence lifetime transition over time. Retina. 2019;39:879–88.
pubmed: 30985551
pmcid: 6510322
doi: 10.1097/IAE.0000000000002519
Ablonczy Z, Gutierrez DB, Grey AC, Schey KL, Crouch RK. Molecule-specific imaging and quantitation of A2E in the RPE. Adv Exp Med Biol. 2012;723:75–81.
pubmed: 22183318
doi: 10.1007/978-1-4614-0631-0_11
Sears AE, Bernstein PS, Cideciyan AV, Hoyng C, Charbel Issa P, Palczewski K, et al. Towards treatment of Stargardt disease: workshop organized and sponsored by the foundation fighting blindness. Transl Vis Sci Technol. 2017;6:6.
pubmed: 28920007
pmcid: 5599228
doi: 10.1167/tvst.6.5.6
Mitsios A, Dubis AM, Moosajee M. Choroideremia: from genetic and clinical phenotyping to gene therapy and future treatments. Ther Adv Ophthalmol. 2018;10:2515841418817490.
pubmed: 30627697
pmcid: 6311551
Vitale AS, Sauer L, Modersitzki NK, Bernstein PS. Fluorescence lifetime imaging ophthalmoscopy (FLIO) in patients with choroideremia. Transl Vis Sci Technol 2020;9:33.
pubmed: 33062396
pmcid: 7533737
doi: 10.1167/tvst.9.10.33
Pagon RA. Retinitis pigmentosa. Surv Ophthalmol. 1988;33:137–77.
pubmed: 3068820
doi: 10.1016/0039-6257(88)90085-9
Dysli C, Schurch K, Pascal E, Wolf S, Zinkernagel MS. Fundus autofluorescence lifetime patterns in retinitis pigmentosa. Investig Ophthalmol Vis Sci. 2018;59:1769–78.
doi: 10.1167/iovs.17-23336
Andersen KM, Sauer L, Gensure RH, Hammer M, Bernstein PS. Characterization of retinitis pigmentosa using fluorescence lifetime imaging ophthalmoscopy (FLIO). Transl Vis Sci Technol. 2018;7:20.
pubmed: 29946494
pmcid: 6016507
doi: 10.1167/tvst.7.3.20
Jackson TL, Nicod E, Simpson A, Angelis A, Grimaccia F, Kanavos P. Symptomatic vitreomacular adhesion. Retina. 2013;33:1503–11.
pubmed: 23714857
doi: 10.1097/IAE.0b013e31829232fd
Jaggi D, Solberg Y, Dysli C, Ebneter A, Wolf S, Zinkernagel MS. Fluorescence lifetime imaging ophthalmoscopy: findings after surgical reattachment of macula-off rhegmatogenous retinal detachment. Retina. 2020;40:1929–37.
pubmed: 31860523
Tett SE, Cutler DJ, Day RO, Brown KF. Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br J Clin Pharmacol. 1989;27:771–9.
pubmed: 2757893
pmcid: 1379804
doi: 10.1111/j.1365-2125.1989.tb03439.x
de Sisternes L, Hu J, Rubin DL, Marmor MF. Localization of damage in progressive hydroxychloroquine retinopathy on and off the drug: inner versus outer retina, parafovea versus peripheral fovea. Investig Ophthalmol Vis Sci. 2015;56:3415–26.
doi: 10.1167/iovs.14-16345
Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF.American Academy of Ophthalmology Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). Ophthalmology. 2016;123:1386–94.
pubmed: 26992838
doi: 10.1016/j.ophtha.2016.01.058
Jorge A, Ung C, Young LH, Melles RB, Choi HK. Hydroxychloroquine retinopathy—implications of research advances for rheumatology care. Nat Rev Rheumatol. 2018;14:693–703.
pubmed: 30401979
doi: 10.1038/s41584-018-0111-8
Sauer LC, Calvo CM, Vitale, AS, Henrie, N, Milliken, CM, Bernstein, PS. Imaging of hydroxychloroquine toxicity with fluorescence lifetime imaging ophthalmoscopy (FLIO). Ophthalmol Retina. 2019;3:814–25.
pubmed: 31345727
doi: 10.1016/j.oret.2019.04.025
Solberg Y, Dysli C, Moller B, Wolf S, Zinkernagel MS. Fluorescence lifetimes in patients with hydroxychloroquine retinopathy. Investig Ophthalmol Vis Sci. 2019;60:2165–72.
doi: 10.1167/iovs.18-26079
Gakamsky A, Duncan RR, Howarth NM, Dhillon B, ButtenschN KK, Daly DJ, et al. Tryptophan and non-tryptophan fluorescence of the eye lens proteins provides diagnostics of cataract at the molecular level. Sci Rep. 2017;7:40375.
pubmed: 28071717
pmcid: 5223181
doi: 10.1038/srep40375
Brauer JL, Schultz R, Klemm M, Hammer M. Influence of lens fluorescence on fluorescence lifetime imaging ophthalmoscopy (FLIO) fundus imaging and strategies for its compensation. Transl Vis Sci Technol. 2020;9:13.
pubmed: 32855860
pmcid: 7422756
doi: 10.1167/tvst.9.8.13
Klemm M, Blum J, Link D, Hammer M, Haueisen J, Schweitzer D. Combination of confocal principle and aperture stop separation improves suppression of crystalline lens fluorescence in an eye model. Biomed Opt Express. 2016;7:3198–210.
pubmed: 27699092
pmcid: 5030004
doi: 10.1364/BOE.7.003198
Schweitzer D, Hammer M, Schweitzer F. Limits of the confocal laser-scanning technique in measurements of time-resolved autofluorescence of the ocular fundus. Biomed Tech. 2005;50:263–7.
doi: 10.1515/BMT.2005.038
Ramm L, Jentsch S, Augsten R, Hammer M. Fluorescence lifetime imaging ophthalmoscopy in glaucoma. Graefe’s Arch Clin Exp Ophthalmol. 2014;252:2025–6.
doi: 10.1007/s00417-014-2813-1
Weller J, Budson A. Current understanding of Alzheimer’s disease diagnosis and treatment. F1000Res. 2018;7:F1000 Faculty Rev-1161.
Bambo MP, Garcia-Martin E, Pinilla J, Herrero R, Satue M, Otin S, et al. Detection of retinal nerve fiber layer degeneration in patients with Alzheimer’s disease using optical coherence tomography: searching new biomarkers. Acta Ophthalmol. 2014;92:e581–2.
pubmed: 24592935
doi: 10.1111/aos.12374
Javaid FZ, Brenton J, Guo L, Cordeiro MF. Visual and ocular manifestations of Alzheimer’s disease and their use as biomarkers for diagnosis and progression. Front Neurol. 2016;7:55.
pubmed: 27148157
pmcid: 4836138
doi: 10.3389/fneur.2016.00055
Jentsch S, Schweitzer D, Schmidtke KU, Peters S, Dawczynski J, Bär KJ, et al. Retinal fluorescence lifetime imaging ophthalmoscopy measures depend on the severity of Alzheimer’s disease. Acta Ophthalmol. 2015;93:e241–7.
pubmed: 25482990
doi: 10.1111/aos.12609
Kwon S, Fang W, Borreli E, Ebraheem A, Marion K, Katayama Y, et al. Fluorescence lifetime imaging ophthalmoscopy in early Alzheimer’s disease. Honolulu, Hawaii, USA: ARVO Annual Meeting; 2018.